Serum levels of arginase I are associated with left ventricular function after myocardial infarction

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1090-1093

  Bekpinar, Seldag ^a   Gurdol, Figen ^a   Unlucerci, Yesim ^a   Develi, Seval ^a   Yilmaz, Akar ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Arginase; Diabetes mellitus; Myocardial infarction; Ventricular dysfunction

Indexed keywords

ARGINASE 1; ARGININE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ARGINASE; ARGININE; CASE-CONTROL STUDIES; HUMANS; MYOCARDIAL INFARCTION; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 80051691141     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.003     Document Type: Article

References (30)

1. Noll G., Luscher T.F. The endothelium in acute coronary syndromes. Eur Heart J 1998, 19(Suppl. C):C30-C38.
2. Fichtlscherer S., Breuer S., Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patients. Circulation 2004, 110:1926-1932.
3. Jenkinson C.P., Grody W.W., Cederbaum S.D. Comparative properties of arginase. Comp Biochem Physiol B Biochem Mol Biol 1996, 114:107-132.
4. Durante W., Liao L., Reyna S.V., Peyton K.J., Schafer A.I. Transforming growth factor-beta (1) stimulates L- arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation 2001, 103:1121-1127.
5. Bachetti T., Comini L., Francolini G., Bastianon D., Valetti B., Cadei M., et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004, 37:515-534.
6. Vanhoutte P.M. Arginine and arginase: endothelial NO synthase double crossed?. Circ Res 2008, 102:866-868.
7. Xu W., Zheng S., Comhair S.A., Janocha A.J., Goggans T., et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004, 18:1746-1748.
8. Morris S.M. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009, 157:922-930.
9. Cavusoglu E., Ruwenda C., Chopra V., Poludasu S., Yanamadala S., Frishman W.H., et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred to coronary angiography. Atherosclerosis 2010, 210:226-231.
10. Böger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119:1592-1600.
11. Solomon S.D., St John Sutton M., Lamas G.A., Plappert T., Rouleau J.L., Skali H., et al. Survival and Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002, 106:1251-1255.
12. Lewis E.F., Moye L.A., Rouleau J.L., Sacks F.M., Arnold J.M., Warnica J.W., et al. CARE Study. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE Study. J Am Coll Cardiol 2003, 42:1446-1453.
13. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological sample by HPLC. Methods Mol Med 2005, 108:263-274.
14. Ubbink J.B., Hayward Vermaak W.J., Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991, 565:441-446.
15. Porembska Z., Kedra M. Early diagnosis of myocardial infarction by arginase activity determination. Clin Chim Acta 1975, 60:355-361.
16. Dumont J., Zureik M., Cottel D., Montaye M., Ducimetière P., Amouyel P., et al. Association of arginase-1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. J Med Genet 2007, 44:526-531.
17. Harpster M.H., Bandyopadhyay S., Thomas D.P., Ivanov P.S., Keele J.A., Pineguina N., et al. Earliest changes in the left ventricular transcriptome postmyocardial infarction. Mamm Genome 2006, 17:701-715.
18. Hein T.W., Zhang C., Wang W., Chang C.I., Thengchaisri N., Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arteriols: counteracting role of arginase. FASEB J 2003, 17:2328-2330.
19. Jung C., Gonon A.T., Sjöquist P.-O., Lundberg J.D., Pernow J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 2010, 85:147-154.
20. Schulman S.P., Becker L.C., Kass D.A., Champion H.C., Terrin M.L., Forman S., et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006, 295:58-64.
21. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5(12):953-964.
22. Troidl C., Möllmann H., Nef H., Masseli F., Voss S., Szardien S., et al. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 2009, 13:3485-3496.
23. Booth G.L., Kapral M.K., Fung K., Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population based retrospective cohort study. Lancet 2006, 368:29-36.
24. Murcia A.M., Hennekens C.H., Lamas G.A., Jiménez-Navarro M., Rouleau J.L., Flaker G.C., et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004, 164:2273-2279.
25. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000, 102:1014-1019.
26. Kashyap S.R., Lara A., Zhang R., Park Y.M., DeFronzo R.A. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 2008, 31:134-139.
27. Duell P.B., Malinow M.R. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997, 8:28-34.
28. Osorio A., Ortega E., Ruiz-Requena E. Two models of homocysteine behaviour in acute myocardial infarction. Clin Biochem 2008, 41:277-281.
29. Qujeq D., Omran T.S., Hosini L. Correlation between total homocysteine, low density lipoprotein cholesterol and high density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001, 34:97-101.
30. Bønaa K.H., Njølstad I., Uerland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.